SCIVISION BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.5 TWD | +0.95% |
|
+0.95% | +37.24% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.04B 31.98M | Sales 2025 * | 1.47B 45.35M | Capitalization | 7.21B 223M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 6.96 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.91 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.95% | ||
| 1 week | +0.95% | ||
| Current month | -0.47% | ||
| 1 month | -6.99% | ||
| 3 months | +42.00% | ||
| 6 months | +38.85% | ||
| Current year | +37.24% |
1 week
103.50
108.00
1 month
99.20119.00
Current year
73.20119.00
1 year
67.10119.00
3 years
38.80119.00
5 years
33.36119.00
10 years
30.63119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kai Cheng Han
CEO | Chief Executive Officer | - | 02-06-13 |
Chun Nan Lin
DFI | Director of Finance/CFO | - | - |
Ju Ling Kuo
DFI | Director of Finance/CFO | - | 03-07-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 11-06-08 | |
Kai Cheng Han
CEO | Chief Executive Officer | - | 02-06-13 |
Ming Kung Yang
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 106.5 | +0.95% | 393 464 |
| 24-05-06 | 105.5 | -1.40% | 466,621 |
| 24-05-03 | 107 | +0.94% | 670,145 |
| 24-05-02 | 106 | -0.93% | 268,183 |
| 24-04-30 | 107 | +1.42% | 430,223 |
End-of-day quote Taiwan S.E., May 06, 2024
More quotes
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
106.5
TWD
Average target price
131
TWD
Spread / Average Target
+23.00%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +37.24% | 221M | |
| +10.91% | 124B | |
| -7.48% | 10.93B | |
| +5.47% | 9.31B | |
| +20.74% | 7.6B | |
| +35.84% | 5.29B | |
| +8.28% | 3.45B | |
| -6.75% | 2.79B | |
| -4.71% | 2.3B | |
| -0.04% | 2.23B |
- Stock Market
- Equities
- 1786 Stock